Lake Street Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $41
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
Lake Street analyst Daniel Brims initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Buy rating and announces Price Target of $41.
Lake Street analyst Daniel Brims initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Buy rating and announces Price Target of $41.